deferitazole (SHP602) / Takeda - LARVOL DELTA

Treatment of Iron Overload Requiring Chelation Therapy (clinicaltrials.gov) - P2; N=50; Suspended; Sponsor: Shire; Initiation date: Apr 2014 ➔ Nov 2014

Clinical • Trial initiation date • Beta-Thalassemia • Genetic Disorders • Hematological Disorders • Metabolic Disorders • MRI

Treatment of Iron Overload Requiring Chelation Therapy (clinicaltrials.gov) - P2; N=50; Suspended; Sponsor: Shire; Not yet recruiting ➔ Suspended

Clinical • Trial suspension • Beta-Thalassemia • Genetic Disorders • Hematological Disorders • Metabolic Disorders • MRI

Treatment of Iron Overload Requiring Chelation Therapy (clinicaltrials.gov) - P2; N=50; Suspended; Sponsor: Shire

Clinical • New P2 trial • Beta-Thalassemia • Genetic Disorders • Hematological Disorders • Metabolic Disorders • MRI

Treatment of Iron Overload Requiring Chelation Therapy (clinicaltrials.gov) - P2; N=0; Withdrawn; Sponsor: Shire; Trial primary completion date: Oct 2015 ➔ Oct 2014

Clinical • Trial primary completion date • Beta-Thalassemia • Genetic Disorders • Hematological Disorders • Metabolic Disorders • MRI

Treatment of Iron Overload Requiring Chelation Therapy (clinicaltrials.gov) - P2; N=0; Withdrawn; Sponsor: Shire; Initiation date: Oct 2014 ➔ Jul 2014; Trial primary completion date: Oct 2014 ➔ Jul 2014

Clinical • Trial initiation date • Trial primary completion date • Beta-Thalassemia • Genetic Disorders • Hematological Disorders • Metabolic Disorders • MRI

Treatment of Iron Overload Requiring Chelation Therapy (clinicaltrials.gov) - P2; N=0; Withdrawn; Sponsor: Shire; N=50 ➔ 0; Suspended ➔ Withdrawn

Clinical • Enrollment change • Trial withdrawal • Beta-Thalassemia • Genetic Disorders • Hematological Disorders • Metabolic Disorders • MRI

THE INCREASING FERRITIN SERUM LEVEL AND OVERALL SURVIVAL IN PATIENTS WITH MALIGNANT LYMPHOMAS (EHA 2018) - "These findings allow to conclude the patients with hyperferritinemia at the onset of disease in the group of patients with poor prognosis and lower overall survival. The high ferritin serum level in patients without prior blood transfusion should consider as a significant marker of poor prognosis. The analysis of ferrokinetics in patients with lymphomas before starting the chemotherapy make it possible to use preventive approach for combining groups with poor prognosis and elimination of negative factors."

Clinical • Hematological Malignancies • Hodgkin Lymphoma • Leukemia • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology